Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

PURPOSE: To examine circulating tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive assay in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAT). PATIENTS AND METHODS: We identified responders (RCB-0/1) and matched n...

Descripción completa

Detalles Bibliográficos
Autores principales: Parsons, Heather A., Blewett, Timothy, Chu, Xiangying, Sridhar, Sainetra, Santos, Katheryn, Xiong, Kan, Abramson, Vandana G., Patel, Ashka, Cheng, Ju, Brufsky, Adam, Rhoades, Justin, Force, Jeremy, Liu, Ruolin, Traina, Tiffany A., Carey, Lisa A., Rimawi, Mothaffar F., Miller, Kathy D., Stearns, Vered, Specht, Jennifer, Falkson, Carla, Burstein, Harold J., Wolff, Antonio C., Winer, Eric P., Tayob, Nabihah, Krop, Ian E., Makrigiorgos, G. Mike, Golub, Todd R., Mayer, Erica L., Adalsteinsson, Viktor A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029037/
https://www.ncbi.nlm.nih.gov/pubmed/36945501
http://dx.doi.org/10.1101/2023.03.06.23286772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029037/
https://www.ncbi.nlm.nih.gov/pubmed/36945501
http://dx.doi.org/10.1101/2023.03.06.23286772

Ejemplares similares